Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
AKBA — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

11.21

Margin Of Safety %

8

Put/Call OI Ratio

0.14

EPS Next Q Diff

0.05

EPS Last/This Y

0.03

EPS This/Next Y

-0.11

Price

1.39

Target Price

4.4

Analyst Recom

1

Performance Q

-8.61

Upside

-118.8%

Beta

0.4

Ticker: AKBA



16 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09AKBA1.3450.180.0034093
2026-03-10AKBA1.3750.180.0134519
2026-03-11AKBA1.3950.180.0034593
2026-03-12AKBA1.410.170.0235726
2026-03-13AKBA1.40.170.0235726
2026-03-17AKBA1.490.180.6635881
2026-03-18AKBA1.450.170.1635888
2026-03-20AKBA1.410.170.0435922
2026-03-25AKBA1.40.150.0034617
2026-03-26AKBA1.3850.150.0034574
2026-03-27AKBA1.3450.150.0034633
2026-03-30AKBA1.330.152.3334832
2026-03-31AKBA1.3850.140.0034545
2026-04-01AKBA1.410.140.2634589
2026-04-06AKBA1.320.140.0034949
2026-04-07AKBA1.390.140.5734953
DateSymbolLatestP/C OIP/C VolTotal OI
16 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09AKBA1.35-120.2- 0.01
2026-03-10AKBA1.38-120.2- 0.01
2026-03-11AKBA1.40-120.2- 0.01
2026-03-12AKBA1.40-120.2- 0.01
2026-03-13AKBA1.47-120.2- 0.01
2026-03-17AKBA1.49-120.2- 0.01
2026-03-18AKBA1.45-120.2- 0.01
2026-03-19AKBA1.43-120.2- 0.01
2026-03-20AKBA1.41-120.2- 0.01
2026-03-23AKBA1.40-120.2- 0.01
2026-03-24AKBA1.37-120.2- 0.01
2026-03-25AKBA1.40-120.2- 0.01
2026-03-26AKBA1.38-120.2- 0.01
2026-03-27AKBA1.35-120.2- 0.01
2026-03-30AKBA1.33-120.2- 0.01
2026-03-31AKBA1.38-120.2- 0.01
2026-04-01AKBA1.41-120.2- 0.01
2026-04-02AKBA1.38-120.2- 0.01
2026-04-06AKBA1.32-120.2- 0.01
2026-04-07AKBA1.39-120.2- 0.01
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09AKBA-5.81-2.0512.07
2026-03-10AKBA-5.81-2.0512.07
2026-03-11AKBA-5.81-2.0511.49
2026-03-12AKBA-5.81-2.0511.49
2026-03-13AKBA-5.81-2.0511.49
2026-03-18AKBA-5.81-2.0411.49
2026-03-19AKBA-5.81-2.0411.49
2026-03-20AKBA-5.81-2.0411.49
2026-03-23AKBA-5.81-1.9811.49
2026-03-24AKBA-5.81-1.9811.49
2026-03-25AKBA-5.81-1.9811.21
2026-03-26AKBA-5.81-1.9811.21
2026-03-27AKBA-5.81-1.9811.21
2026-03-30AKBA-5.81-1.9811.21
2026-03-31AKBA-5.81-1.9811.21
2026-04-01AKBA-5.81-1.9811.21
2026-04-02AKBA-5.81-1.9811.21
2026-04-06AKBA-5.81-1.9811.21
2026-04-07AKBA-5.81-1.9811.21
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS​

-0.05

Avg. EPS Est. Current Quarter

-0.01

Avg. EPS Est. Next Quarter

-0.01

Insider Transactions

-5.81

Institutional Transactions

-1.98

Beta

0.4

Average Sales Estimate Current Quarter

51

Average Sales Estimate Next Quarter

54

Fair Value

1.5

Quality Score

81

Growth Score

41

Sentiment Score

40

Actual DrawDown %

67.9

Max Drawdown 5-Year %

-94

Target Price

4.4

P/E

Forward P/E

PEG

P/S

1.57

P/B

11.23

P/Free Cash Flow

5.46

EPS

-0.02

Average EPS Est. Cur. Y​

0.01

EPS Next Y. (Est.)

-0.09

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2.26

Relative Volume

0.73

Return on Equity vs Sector %

-43.9

Return on Equity vs Industry %

-23.7

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.16

EBIT Estimation

◆ AKBA Healthcare
$1.38
📉
Swing / Pullback
Buy the dip on strong trends
49 /100
WEAK
Trend
2/20
Pullback
13/25
Volume
9/15
Valuation
15/20
TP/AR
2/10
Options
8/10
RSI
50.9
Range 1M
39.3%
Sup Dist
6.3%
🚀
Momentum Growth
Ride accelerating trends
N/A
24 /100
WEAK
Momentum
2/25
Growth
11/30
Estimates
4/20
Inst/Vol
0/15
Options
7/10
EPS Yr
-240%
EPS NY
-117.7%
52W%
8%
💎
Long-Term Value
Quality companies, undervalued
36 /100
WEAK
🟢 BUY +92.7% upside
Quality
9/30
Valuation
18/30
Growth
5/25
Stability
2/10
LT Trend
2/5
Upside
+92.7%
Quality
81
MoS
8%
Click a card to see score breakdown Full Analysis →
Akebia Therapeutics, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 194
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AKBA

Latest News

—
Caricamento notizie per AKBA…
stock quote shares AKBA – Akebia Therapeutics Inc. Stock Price stock today
news today AKBA – Akebia Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AKBA – Akebia Therapeutics Inc. yahoo finance google finance
stock history AKBA – Akebia Therapeutics Inc. invest stock market
stock prices AKBA premarket after hours
ticker AKBA fair value insiders trading